This clinical trial is focused on studying a condition known as Thyroid Eye Disease. This condition can cause the eyes to bulge and become red, swollen, and painful. The study will use a treatment called VRDN-001, which is an experimental medication designed to block a specific protein that may be involved in the disease. The study will also use Sodium Chloride 0.9% Intravenous Infusion, commonly known as normal saline, which is a standard fluid used in medical treatments.

The purpose of this study is to provide access to VRDN-001 for participants who did not respond to previous treatments in earlier studies. The study will assess the safety and effectiveness of VRDN-001 in these participants. Participants will receive the treatment through an intravenous infusion, which means the medication will be given directly into a vein. The study will last for a period of 12 weeks, during which participants will receive several doses of the medication.

Throughout the study, participants will be monitored for any changes in their condition, as well as any side effects they may experience. The study aims to determine if VRDN-001 can help reduce the symptoms of Thyroid Eye Disease in those who have not responded to other treatments. Participants will be closely observed to ensure their safety and to gather information on how well the treatment works.